Business
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising CNS Uptake at American Society of Gene and Cell Therapy 28th Annual Meeting
HYOGO, Japan, May 16, 2025--JCR announced that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy research programs at ASGCT 2025.
About this update from Jcr Pharmaceuticals Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/6452994e84588c661f39d205e03dcb9d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vgEy41e8diSF.XhSRxur3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6452994e84588c661f39d205e03dcb9d","width":480,"height":251}},"lazy":false},{"type":"text","content":"- Research Highlights the Potential of JCR’s Proprietary J-Brain Cargo® Technology to Facilitate Efficient Delivery of an AAV Gene Therapy to the Central Nervous System –","length":170,"tagName":"p","attribs":{}},{"type":"text","content":"HYOGO, Japan, May 16, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") announced today that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy research programs at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, being held May 13-17, 2025, in New Orleans, LA. In an oral presentation, the JCR researcher reported that the Company’s proprietary J-Brain Cargo® (JBC) technology enables the efficient delivery of an adeno-associated virus (AAV) gene therapy across the blood-brain barrier (BBB) and into the central nervous system (CNS) in mice, monkeys, and several animal models of CNS diseases.","length":698,"tagName":"p"},{"type":"text","content":"We have successfully developed JUST-AAV, a novel AAV vector platform technology designed to enhance targeted delivery and reduce liver tropism, thereby improving safety and efficacy of AAV-based gene delivery technologies to the CNS. JUST-AAV encompasses a range of vector types optimized for various target tissues, including liver-sparing, muscle-targeting, and brain-targeting variants. This proprietary technology holds significant promise for advancing the field of AAV-based gene therapy.","length":494,"tagName":"p"},{"type":"text","content":""These findings represent a significant advancement toward new treatments for previously challenging CNS diseases," said Hiroyuki Sonoda, Ph.D., Director, Senior Managing Executive Officer, and Executive Director, Research Division at JCR Pharmaceuticals. "Our preclinical data demonstrate that our brain-t...